OAT

Flash News: OKX Launches Snap Quest Campaign with 5,000 USDT Reward Pool for Its New Snap Mode Powered by UniSwapX

Retrieved on: 
Monday, March 4, 2024

SINGAPORE, March 4, 2024 /PRNewswire/ -- OKX , a leading Web3 technology company, has issued updates for March 4, 2024.

Key Points: 
  • SINGAPORE, March 4, 2024 /PRNewswire/ -- OKX , a leading Web3 technology company, has issued updates for March 4, 2024.
  • OKX today announced a Snap Quest Campaign , in celebration of the launch of its new Snap Mode powered by UniSwapX.
  • Users who complete tasks including following OKX Web3 on social media and executing a swap transaction on OKX DEX using Snap Mode, can win a chance to claim a share in a prize pool worth 5,000 USDT.
  • OKX Snap Mode allows users to access optimal pricing and swap tokens on Ethereum quickly and intuitively without incurring any gas fees, creating more intuitive trading and comprehensive DeFi experiences.

Foundation Fighting Blindness Launches GYROS, a Natural History Study for People with Gyrate Atrophy

Retrieved on: 
Tuesday, February 6, 2024

COLUMBIA, Md. , Feb. 6, 2024 /PRNewswire/ -- `The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for inherited retinal diseases and dry age-related macular degeneration, is launching a natural history study for people with gyrate atrophy, a rare, vision-robbing inherited retinal disease. The lead investigators for the study are Mandeep S. Singh, MD, PhD, the Andreas C. Dracopoulos Professor of Ophthalmology and Associate Professor of Ophthalmology and Genetic Medicine at the Wilmer Eye Institute and David Valle, MD, Professor of Genetic Medicine and former director of the McKusick-Nathans Department of Genetic Medicine at Johns Hopkins University.

Key Points: 
  • GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.
  • , Feb. 6, 2024 /PRNewswire/ -- `The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for inherited retinal diseases and dry age-related macular degeneration, is launching a natural history study for people with gyrate atrophy, a rare, vision-robbing inherited retinal disease.
  • Known as the Gyrate Atrophy Ocular and Systemic Study (GYROS), the $3.5 million study is informing the design of future clinical trials for gyrate atrophy.
  • Gyrate atrophy is a progressive retinal disease that causes night blindness and loss of peripheral vision, in addition to severe childhood-onset myopia.

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

Retrieved on: 
Monday, January 29, 2024

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices.

Key Points: 
  • PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices.
  • Earlier in January, Philips Respironics announced the discontinuation of many devices used for the treatment and diagnosis of sleep apnea, including CPAP systems.
  • “Scientific data from over a dozen studies, including hundreds of patients, establish ProSomnus devices as safe, effective, and patient preferred.
  • “Philips has been a prominent player in the sleep health industry, providing innovative solutions for sleep apnea and other sleep disorders.

BrandSpark International announces its 21st annual 2024 Best New Product Awards winners, recognizing the Best New Food, Beverage, Beauty, Health, Personal Care, Kids, Pet, Household Care, Home Goods & Footwear, Restaurant Menu Items and Services based on

Retrieved on: 
Monday, January 29, 2024

TORONTO, Jan. 29, 2024 /CNW/ - BrandSpark International has announced the winners of the 21st annual 2024 Best New Product Awards™ ("BNPA"), Canada's largest and most credible new product awards program.

Key Points: 
  • TORONTO, Jan. 29, 2024 /CNW/ - BrandSpark International has announced the winners of the 21st annual 2024 Best New Product Awards™ ("BNPA"), Canada's largest and most credible new product awards program.
  • The winners are 100% consumer-voted and were determined based on real shoppers who purchased these winning products.
  • says Kim Diamond, Vice-President of Best New Product Awards Inc. "At the end of the day, the Best New Product Awards spotlight innovative products that are worth consumers' hard earned dollars."
  • The Best New Product Awards are regarded as Canada's leading new product awards," Levy adds.

ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea

Retrieved on: 
Monday, January 8, 2024

PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of UnitedHealthcare’s updated medical policy (#2024T0525NN) for Obstructive and Central Sleep Apnea, effective March 1, 2024.

Key Points: 
  • PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of UnitedHealthcare’s updated medical policy (#2024T0525NN) for Obstructive and Central Sleep Apnea, effective March 1, 2024.
  • Specifically, the policy states, “Failure of adequate trial of Oral Appliance therapy,” as the new medical policy of UHC.
  • “I am pleased to see this policy update acknowledging the role of oral appliances in the continuum of care for Obstructive Sleep Apnea,” commented Edward T. Sall, MD, DDS, MBA.
  • Modern oral appliances are safe, effective, comfortable, and easy for the patient to insert, remove and keep clean.

Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices

Retrieved on: 
Tuesday, December 19, 2023

PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced the publication of a study by the Cureus Journal of Medical Science, in which the Company’s precision oral appliance therapy (OAT) devices successfully treated patients’ OSA.

Key Points: 
  • PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced the publication of a study by the Cureus Journal of Medical Science, in which the Company’s precision oral appliance therapy (OAT) devices successfully treated patients’ OSA.
  • 80% of severe OSA patients were treated to an AHI of fewer than 20 events per hour with a 50% improvement.
  • My experience with the ProSomnus® EVO® precision oral appliance is that it exceeds the American Academy of Sleep Medicine (AASM) and the American Academy of Dental Sleep Medicine (AADSM) standards for efficacy.
  • “These studies demonstrate that precision oral devices offer consistent efficacy across multiple clinical and hospital settings, and are associated with reliable adherence.

Three Articles in the Journal of Pharmaceutical Analysis Uncover Previously Unknown Drug and Disease Mechanisms

Retrieved on: 
Friday, December 15, 2023

XI'AN, China, Dec. 15, 2023 /PRNewswire/ -- Long-term use of analgesics such as morphine leads to "tolerance" that reduces drug efficacy. In such cases, dose escalation may be required to achieve the same analgesic effects. The key molecular mechanism of morphine tolerance is its inefficiency in inducing mu-opioid receptor (MOR) endocytosis. None of the currently available strategies to counter morphine tolerance address this underlying molecular mechanism. Moreover, understanding how drugs work is crucial to determine their efficacy. There is also an unmet need for new diagnostic biomarkers that can help identify diseases at an early stage. The October issue of JPA features three articles that address these issues and systematically lay a foundation for future studies and treatment strategies.

Key Points: 
  • XI'AN, China, Dec. 15, 2023 /PRNewswire/ -- Long-term use of analgesics such as morphine leads to "tolerance" that reduces drug efficacy.
  • The October issue of JPA features three articles that address these issues and systematically lay a foundation for future studies and treatment strategies.
  • In the second study , researchers dug deeper into the anticancer mechanisms of the drug 'pracinostat,' which is a histone deacetylase inhibitor (HDACi).
  • Corresponding author Prof. Xinan Wu speculates by saying, "Our findings could aid in adjusting drug dosage or predicting renal injury via OAT channels."

ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences

Retrieved on: 
Thursday, September 14, 2023

FLOSAT is an ongoing prospective, independent, head-to-head, crossover study comparing the effectiveness of precision OAT as first-line treatment versus CPAP therapy.

Key Points: 
  • FLOSAT is an ongoing prospective, independent, head-to-head, crossover study comparing the effectiveness of precision OAT as first-line treatment versus CPAP therapy.
  • ProSomnus EVO™ devices are being used exclusively for the precision OAT arm of the study.
  • The study concluded, among other findings, that precision OAT was effective among 90% of moderate OSA patients and 85% of severe OSA patients.
  • Based on both its efficacy and superior adherence, the data shows that precision oral therapy is suited to become a first-line therapy for the widespread health emergency that is Obstructive Sleep Apnea.”

Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea

Retrieved on: 
Wednesday, August 23, 2023

PLEASANTON, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), announced updated clinical trial data, presented at the ProSleep 2023 Users Conference earlier this month. The updated data indicate that the First Line Obstructive Sleep Apnea Treatment study (FLOSAT) is on track to achieve all endpoints.

Key Points: 
  • The updated data indicate that the First Line Obstructive Sleep Apnea Treatment study (FLOSAT) is on track to achieve all endpoints.
  • FLOSAT is an ongoing, prospective, independent, head-to-head study comparing the effectiveness of precision OAT as first-line treatment versus CPAP therapy.
  • In July , ProSomnus announced plans to design a head-to-head clinical trial comparing precision OAT and HNS in treating patients with severe OSA.
  • “The updated data and analysis from FLOSAT is validation that precision oral appliance therapy with ProSomnus devices is an effective front-line treatment for moderate to severe OSA,” said Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus.

'My First MPC Wallet' is here: UXUY Launches Comprehensive Public Testing

Retrieved on: 
Sunday, August 13, 2023

The global public beta testing event for ' My First MPC Wallet ' will commence at midnight (UTC) on August 14th.

Key Points: 
  • The global public beta testing event for ' My First MPC Wallet ' will commence at midnight (UTC) on August 14th.
  • Users who successfully participate in the beta testing will receive UXUY credit gas quota, on-chain OAT commemorative badges, and a share of the 10,000 USDT prize pool.
  • During the global public beta testing event for 'My First MPC Wallet,' the first 10,000 participants will each enjoy a 100 USDT gas credit quota.
  • After the conclusion of the 'My First MPC Wallet' global beta testing event, the UXUY team will publicly announce the list of winners and distribute rewards to your UXUY account.